Jalandhar Online

DelveInsight’s, “Eczema Pipeline Insight, 2022” report provides comprehensive insights about 100+ companies and 100+ pipeline drugs in Eczema pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Key takeaways from the Eczema Pipeline Insight Report

• DelveInsight’s Eczema Pipeline report depicts a robust space with 100+ active players working to develop 150+ pipeline therapies for Eczema.
• The leading Eczema Companies such as Kymab, BiomX, LEO Pharma, GlaxoSmithKline, Arjil Pharmaceuticals, SCM Lifescience, Sun Pharmaceutical Industries, Brickell Biotech Inc, Dermira, AstraZeneca, Kyowa Kirin, UCB Biopharma, Arcutis Biotherapeutics, and others are evaluating new Eczema drugs to improve the treatment landscape.
• Promising Eczema Pipeline therapies such as alitretinoin, E45 Eczema Repair Emollient, Dupilumab, Lebrikizumab, Baricitinib, Topical corticosteroid, and others are under different phases of Eczema clinical trials.
• The companies and academics are working to assess challenges and seek opportunities that could influence Eczema R&D. The therapies under development are focused on novel approaches to treat/improve Eczema.
• In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Eczema collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Get an overview of the Eczema Pipeline landscape @ Eczema Emerging Therapies

Eczema Overview

Eczema, also known as atopic dermatitis, is the most common form of dermatitis. Genetic as well as environmental factors are thought to play a part in the pathogenesis. Eczema is most commonly seen in children but can be seen in adults. People with the disease tend to have dry, itchy skin that is prone to infection. Eczema is commonly known as the “”itch that rashes”” due to dry skin that leads to a rash as a result of scratching or rubbing. The most important treatment of eczema is skin hydration followed by topical steroids for flare-ups. The lifetime prevalence of atopic dermatitis is about 15-30% in children and 2-10% in adults. About 60% of cases will develop within the first year of life. The prevalence of atopic dermatitis is more common in rural rather than urban areas. This incidence which emphasizes the link to lifestyle and environment factors in the mechanisms of AD.

Symptoms of eczema include: A red rash or red patches of skin, especially inside the folds of the elbows and knees, itching, dry skin, which can crack and possibly bleed. The location of eczema may change with age. In infants and young children, eczema is usually located on the cheeks, outside of the elbows and on the knees. In older children and adults, eczema is typically on the hands and feet, the arms and on the back of knees. Symptoms can be painful, including blisters, and the skin may change color. The itch associated with eczema can be severe, often interrupting sleep. Scratching of the skin may lead to an infection. Infants with eczema may rub against bedding or other things to relieve the itch. Allergists are specially trained to treat skin conditions, such as eczema, which are often related to an allergic response. Children and adults diagnosed with eczema can manage the condition with the guidance of an allergist.

Latest Breakthroughs of Eczema Treatment Landscape

• LP 0145, is an anti-inflammatory monoclonal antibody under development for atopic dermatitis. Currently, the drug is being developed in the Phase II stage of clinical trial evaluation for the treatment of Eczemas.
• BX005, a topical phage cocktail that targets Staphylococcus aureus (S. aureus), a bacteria associated with the manifestation of the disease. In preclinical in vitro studies, BX005 was shown to be active against over 90% of strains of S. aureus isolated from the skin of subjects from U.S. and Europe, including antibiotic resistant strains. Currently, the drug is being developed in the Phase I/II stage of clinical trial evaluation for the treatment of Atopic Dermatitis.
• Amlitelimab SAR445229 (formerly KY1005) is a human monoclonal antibody that targets OX40L, a key regulator of the immune system. Amlitelimab is designed to rebalance the immune system by blocking inappropriate activation and proliferation of ‘pro-inflammatory’ effector T cells and promoting expansion of ‘anti-inflammatory’ regulatory T cells, without broad suppression of the immune system. It is believed this mechanism-of-action means Amlitelimab could be applicable to a range of autoimmune and inflammatory diseases. In Phase I clinical trial in healthy volunteers, Amlitelimab was able to block T cell-driven skin inflammation while being well tolerated. It is believed the immune-modulating mechanism of Amlitelimab has broad potential therapeutic application in multiple diseases caused by immune dysregulation. Currently, the drug is being developed in the Phase II stage of clinical trial evaluation for the treatment of Eczema.

Request a sample and discover the recent advances in Eczema treatment drugs @ Eczema Pipeline Report

Eczema Emerging Drugs

• Amlitelimab: Kymab
• BX 005: BiomX
• LP 0145: LEO Pharma

DelveInsight’s Eczema Pipeline Report covers around 100+ products under different phases of clinical development like-

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Learn more about the emerging Eczema pipeline therapies @ Eczema Clinical Trials

Scope of the Eczema Pipeline Report

• Coverage- Global
• Eczema Therapeutic Assessment
• Assessment by Product Type
• Assessment by Stage and Product Type
• Assessment by Route of Administration
• Assessment by Stage and Route of Administration
• Assessment by Molecule Type
• Assessment by Stage and Molecule Type
• Eczema Companies- Kymab, BiomX, LEO Pharma, GlaxoSmithKline, Arjil Pharmaceuticals, SCM Lifescience, Sun Pharmaceutical Industries, Brickell Biotech Inc, Dermira, AstraZeneca, Kyowa Kirin, UCB Biopharma, Arcutis Biotherapeutics, and others
• Eczema Therapies- alitretinoin, E45 Eczema Repair Emollient, Dupilumab, Lebrikizumab, Baricitinib, Topical corticosteroid, and others

Dive deep into rich insights for new drugs for Eczema treatment, visit @ Eczema Drugs

Table of content

1. Introduction
2. Executive Summary
3. Eczema: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Eczema– DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. Drug name : Company name
9. Mid Stage Products (Phase II)
10. Amlitelimab: Kymab
11. Early Stage Products (Phase I)
12. Drug name : Company name
13. Preclinical and Discovery Stage Products
14. Inactive Products
15. Eczema Key Companies
16. Eczema Key Products
17. Eczema- Unmet Needs
18. Eczema- Market Drivers and Barriers
19. Eczema- Future Perspectives and Conclusion
20. Eczema Analyst Views
21. Eczema Key Companies
22. Appendix

For further information on the Eczema pipeline therapeutics, reach out @ Eczema Treatment Drugs

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/